Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]

• DOI: 10.5588/ijtld.11.0414
• Publication Date: 2012-02-10T19:34:37Z
• Authors: M. C. Payen; S. De Wit; C. Martin; R. Sergysels; I. Muylle; Y. Van Laethem; N. Clumeck
• Keywords: Antimycobacterial; Bedaquiline; Regimen; Culture conversion; Extensively drug-resistant tuberculosis

Mycobacterium tuberculosis strains resistant to almost all available anti-tuberculosis drugs are an increasing threat public health worldwide. Among existing with potential antimycobacterial effects, the combination of meropenem clavulanate has been shown have potent in vitro bactericidal activity against extensively drug-resistant (XDR-TB). To explore its clinical efficacy, a meropenem-clavulanate-containing salvage regimen was started six patients severe pulmonary XDR-TB, association only one or two remaining active second-line drugs. Encouraging preliminary data detailed and discussed.